Effects of a magnesium/aluminium hydroxide-containing antacid, cimetidine or ranitidine on the pharmacokinetics of metrifonate and its metabolite DDVP

Clinical Drug Investigation

Volumn 17, Issue 1, 1999, Pages 67-77

  Heinig, Roland ^a   Boettcher, M ^a   Herman Gnjidic, Z ^b   Pierce, C H ^c  

^a BAYER AG   (Germany)

^b Bayer Inc   (Canada)

^c LAB Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALUMINUM MAGNESIUM HYDROXIDE; ANTIULCER AGENT; CIMETIDINE; METRIFONATE; NOOTROPIC AGENT; RANITIDINE;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0032900741     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199917010-00008     Document Type: Article

References (29)

1. Nordgren I, Holmstedt B. Metrifonate: A review. Curr Res Alzheimer Ther 1988; 2: 281-8
2. Lamb HM, Faulds D. Metrifonate. Drugs Aging 1997; 11 (6): 490-6
3. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res 1996; 21 (3): 331-7
4. Heinig R, Versavel M, Breuel HP, et al. Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers [abstract no. 39-26 and poster]. Biol Psychiatry 1997; 42 Suppl. 1S: 94S
5. Schmidt BH, Heinig R. The pharmacological basis for metrifonate's favourable tolerability in the treatment of Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9 Suppl. 2: 15-9
6. Kronforst-Collins MA, Moriearty PL, Ralph M, et al. Metrifonate treatment enhances acquisition of eyeblink conditioning in aging rabbits. Pharmacol Biochem Behav 1997; 56 (1): 103-10
7. Becker RE, Colliver J, Elble R, et al. Effects of metrifonate, a long-acting cholinesterase inhibitor, in Alzheimer Disease: report of all open trial. Drug Dev Res 1990; 19: 425-34
8. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology 1998; 50: 1222-30
9. McKeith IG. The clinical trial protocol of the Metrifonate in ALzheimer's Trial (MALT). Dement Geriatr Cogn Disord 1998; 9 Suppl. 2: 2-7
10. Statistics Canada. The health of Canadians. Report of the Canada Health Survey. Ottawa, Ontario: Health and Welfare Canada, 1982: CN 82-538E
11. Sadowski DC. Drug interactions with antacids - mechanisms and clinical significance. Drug Saf 1994; 11 (6): 395-407
12. Neuvonen PJ, Kivisto KT. Enhancement of drug absorption by antacids. An unrecognised drug interaction. Clin Pharmacokinet 1994; 27 (2): 120-8
13. Smith SR, Kendall MJ. Ranitidine versus cimetidine. A camparison of their potential to cause clinically important drug interactions. Clin Pharmacokinet 1988; 15 (1): 44-56
14. Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Saf 1992; 7 (4): 245-67
15. Villén T, Aden Abdi Y, Ericsson Ö, et al. Determination of metrifonate and dichlorvos in whole blood using gas chromatography and gas chromatography-mass spectrometry. J Chromatogr 1990; 529: 309-17
16. Commission of the European Communities/CPMP. Note for Guidance: Working Party on Quality of Medicinal Products: Analytical Validation. 1989; III/844/87-EN
17. Ellman GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88-95
18. Knedel M, Böttger R. Eine kinetische Methode zur Bestimmung der Aktivität der Pseudocholinesterase. Klin Wochenschr 1967; 45: 325-7
19. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol 1990; 28: 72-8
20. Pabst G, Jaeger H. Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 1990; 38: 5-10
21. Pettigrew LC, Bieber F, Lettieri J, et al. Pharmacokinetics, pharmacodynamics, and safety of metrifonate in patients with Alzheimer's disease. J Clin Pharmacol 1998; 38: 236-45
22. Aden-Abdi Y, Villén T, Ericsson Ö, et al. Metrifonate in healthy volunteers: interrelationship between pharmacokinetic properties, cholinesterase inhibition and side-effects. Bull World Health Organ 1990; 68 (6): 731-6
23. Aden-Abdi Y, Villén T. Pharmacokinetics of metrifonate and its rearrangement product dichlorvos in whole blood. Pharmacol Toxicol 1991; 68: 137-9
24. Nordgren I, Bengtsson E, Holmstedt B, et al. Levels of metrifonate and dichlorvos in plasma and erythrocytes during treatment of schistosomiasis with Bilarcil®. Acta Pharmacol Toxicol 1981; 49 Suppl. V: 79-86
25. Nordgren I. Quantitation of metrifonate and dichlorvos in blood and tissues by gas chromatography-mass spectrometry. Fund Appl Toxicol 1981; 1: 230-7
26. Nordgren I, Holmstedt B, Bengtsson E, et al. Plasma levels of metrifonate and dichlorvos during treatment of schistosomiasis with Bilarcil®. Am J Trop Med Hyg 1980; 29 (3): 426-30
27. Unni LK, Womack C, Hannant ME, et al. Pharmacokinetics and pharmacodynamics of metrifonate in humans. Meth Find Exp Clin Pharmacol 1994; 16 (4): 285-9
28. Aden-Abdi Y, Villén T, Gustafsson LL, et al. Methodological commentary on the analysis of metrifonate and dichlorvos in biological samples. J Chromatogr 1993; 612: 336-7
29. 3H-Trichlorphon zu DDVP. Z Naturforsch 1969; 24b: 663-4